Intense pulsed light treatment for the management of meibomian gland dysfunction

Curr Opin Ophthalmol. 2024 Jul 1;35(4):322-328. doi: 10.1097/ICU.0000000000001055. Epub 2024 May 1.

Abstract

Purpose of review: Meibomian gland dysfunction (MGD) is one of the most common disorders encountered by ophthalmologists, and its management can prove challenging for both clinicians and patients. Intense pulsed light (IPL), which has been historically used in the field of dermatology, has emerged as a tool to help improve meibomian gland function. The goal of this review is to assess the clinical efficacy, utility, and safety of IPL for the treatment of MGD.

Recent findings: In recent randomized controlled trials, IPL has been shown to improve meibomian gland function, and subsequently tear film quality and dry eye symptoms. The mechanism of action still remains unclear. Recent literature suggests that IPL may also be used in conjunction with other therapies, such as meibomian gland expression, low-level light therapy, and thermal pulsation. Careful attention should be placed on each patient's Fitzpatrick skin type, as well as protecting the ocular structures to reduce the risk of adverse effects. Cost, accessibility, as well as a limited duration of efficacy may be drawbacks.

Summary: There is significant evidence supporting that IPL may be used as a potential well tolerated and effective treatment for MGD, though there are certain caveats regarding its long-term efficacy, accessibility, and cost.

Publication types

  • Review

MeSH terms

  • Dry Eye Syndromes / physiopathology
  • Dry Eye Syndromes / therapy
  • Humans
  • Intense Pulsed Light Therapy* / methods
  • Meibomian Gland Dysfunction* / therapy
  • Meibomian Glands
  • Treatment Outcome